Insights on SLE Therapy and Biomarkers in Lupus Management

The chapter delves into the significance of anifrolumab, rituximab, or belimumab in treating SLE patients with high interferon signature, lymphopenia, and multiple autoantibodies. It also explores the effectiveness of anifrolumab on skin and joints influenced by interferon alpha, and the challenges of using proteinuria and biopsies as measures for SLE management.